Skip to main content
Back
OGN logo

Organon & Co.

Data quality: 100%
Oversold
OGN
NYSE Healthcare Drug Manufacturers - General
$6.09
▲ $0.06 (1.00%)
Mkt Cap: 1.59B
Day Range
$5.77 $6.18
52-Week Range
$5.77 $15.85
Volume
5,919,955
50D / 200D Avg
$7.72 / $8.64
Prev Close
$6.03

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 8.5 0.4
P/B 2.1 2.9
ROE % 30.6 3.8
Net Margin % 3.0 3.9
Rev Growth 5Y % -0.4 10.0
D/E 11.7 0.2

Key Takeaways

Revenue declined -0.35% annually over 5 years
Earnings declined -78.36% over the past year
ROE of 30.56% indicates high profitability
Debt/Equity of 11.70 — high leverage
Generating 538.00M in free cash flow
P/E of 8.48 — trading at a low valuation

Growth

Revenue Growth (5Y)
-0.35%
Revenue (1Y)-2.92%
Earnings (1Y)-78.36%
FCF Growth (3Y)0.00%

Quality

Return on Equity
30.56%
ROIC10.09%
Net Margin3.01%
Op. Margin20.67%

Safety

Debt / Equity
11.70
Current Ratio1.82
Interest Coverage2.55

Valuation

P/E Ratio
8.48
P/B Ratio2.11
EV/EBITDA7.64
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2.92% Revenue Growth (3Y) -0.38%
Earnings Growth (1Y) -78.36% Earnings Growth (3Y) -57.25%
Revenue Growth (5Y) -0.35% Earnings Growth (5Y) -39.00%
Profitability
Revenue (TTM) 6.22B Net Income (TTM) 187.00M
ROE 30.56% ROA 1.45%
Gross Margin 54.09% Operating Margin 20.67%
Net Margin 3.01% Free Cash Flow (TTM) 538.00M
ROIC 10.09% FCF Growth (3Y) 0.00%
Safety
Debt / Equity 11.70 Current Ratio 1.82
Interest Coverage 2.55 Dividend Yield 0.05%
Valuation
P/E Ratio 8.48 P/B Ratio 2.11
P/S Ratio 0.26 PEG Ratio -0.13
EV/EBITDA 7.64 Dividend Yield 0.05%
Market Cap 1.59B Enterprise Value 9.81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.22B 6.40B 6.26B 6.17B 6.30B
Net Income 187.00M 864.00M 1.02B 917.00M 1.35B
EPS (Diluted) 0.72 3.33 3.99 3.59 5.33
Gross Profit 3.36B 3.72B 3.75B 3.88B 3.92B
Operating Income 1.29B 1.49B 1.33B 1.71B 1.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12.87B 13.10B 12.06B 10.96B 10.68B
Total Liabilities 12.12B 12.63B 12.13B 11.85B 12.19B
Shareholders' Equity 752.00M 472.00M -70.00M -892.00M -1.51B
Total Debt 8.80B 9.04B 8.93B 9.11B 9.36B
Cash & Equivalents 574.00M 675.00M 693.00M 706.00M 737.00M
Current Assets 4.35B 4.35B 4.51B 3.93B 3.76B
Current Liabilities 2.39B 2.72B 2.92B 2.51B 2.60B

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#166 of 655
49

Recent Activity

Entered Contrarian Investing (David Dreman)
Mar 24, 2026